重組小鼠 Epidermal Growth Factor 蛋白產品說明：
純度：> 95 % as determined by SDS-PAGE
內毒素：< 1.0 EU per μg of the protein as determined by the LAL method
生物活性：1.Measured in a cell proliferation assay using Balb/3T3 mouse embryonic fibroblast cells. The ED50 for this effect is typically 0.1-0.6 ……
蛋白構建：A DNA sequence encoding the mouse EGF (P01132) (Asn977-Arg1029) was expressed and purified with two additional amino acids (Gly & Pro) at the N-terminus.
Accession#P01132
表達宿主：HEK293 Cells
種屬：Mouse
預測 N 端：Gly
分子量：The recombinant mouse EGF consists of 55 amino acids and predicts a molecular mass of 6.2 KDa. It migrates as an approximately 14 KDa band in SDS-PAGE under reducing conditions.
緩沖液：Lyophilized from sterile PBS, pH 7.4.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hardcopy of datasheet.
運輸方式：In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
穩定性 & 儲存條件：Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
復溶：A hardcopy of datasheet with reconstitution instructions is sent along with the products. Please refer to it for detailed information.
歡迎去義翹神州網查看重組小鼠 Epidermal Growth Factor 蛋白詳細信息。
北京義翹神州科技股份有限公司作為國家高新-技術企業，主要從事生物試劑研發、生產、銷售并提供技術服務的生物科技公司，主要業務包括重組蛋白、抗體、基因和培養基等產品，以及重組蛋白、抗體的開發和生物分析檢測等服務，同時也為制藥公司或者生物技術公司提供單克隆抗體候選藥物的臨床前規模生產服務。義翹神州擁有多項核心技術以及從研發生產到放大生產的技術平臺，為重組蛋白或者抗體試劑的高通量、高效率研發生產提供保障，旨在為制藥企業和生命科學研究機構提供高質量的生物試劑產品和高水平的技術服務。
北京義翹神州始終秉承"全面致力于為生命科學研究人員提供高品質的重組蛋白和抗體等科研工具試劑以及一站式技術服務"的理念，堅持自主研發，自主生產，依托技術平臺，打造國際生物試劑品牌。義翹神州提供"一站式"技術服務，從基因序列到1-30克純化后單克隆抗體僅需幾周的時間，是目前范圍內抗體生產速度領-先的企業之一。我們也為制藥公司或者生物技術公司提供單克隆抗體候選藥物的臨床前規模生產服務。
